News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Mesothelioma Patient Featured on ABC’s BostonMed
- Stand Up 2 Cancer Telethon Scheduled for September 10th – Tune In to Join the Cause to Raise Funds for Mesothelioma and Other Cancers
- All Forms of Asbestos Shown to Cause Mesothelioma
- Mesothelin Finding Could Lead to Early Detection of Mesothelioma
- New York Attorney Calls for International Ban on Mesothelioma-Causing Asbestos
- Protein Can be Reliable for Diagnosing Malignant Mesothelioma
- Biomarker Successes Remain Elusive For Mesothelioma and Cancer Researchers
- Avastin May Not be Effective for Breast Cancer, But is Still an Option for Mesothelioma
- Options for Funding Mesothelioma Research
- Golf Outing to Raise Funds for Mesothelioma Research
Thursday, December 10, 2009
Another new mesothelioma drug clinical trial is slated to begin in December 2009. Australian drug maker Bionomics Ltd plans to conduct a Phase II clinical trial of its anti-cancer drug BNC105. They will conduct the tests on 60 mesothelioma patients in Australia.
The drug has shown great promise thus far by killing cancer cells when testing with solid tumors in animals. Bionomics believes patients will not become resistant to this drug as often happens with other chemotherapy treatments. BNC105 will also undergo a Phase II trial in the United States for the treatment of renal cancer.
The primary goal of this study is to determine the safety and maximum tolerated dose of BNC105 in patients with advanced solid tumors. Bionomics says BNC105 “can extend the life of people suffering from mesothelioma and provide them with a better quality of life.”
Sources:
Bionomics Clinical Trials
The Sydney Morning Herald
© MesotheliomaHelp.Net. All Rights Reserved. Reprinting or republication of this article or any portion of its content is permitted but must include the MesotheliomaHelp.Net link.
Labels: ClinicalTrial, mesothelioma
posted by Nancy Meredith at 7:00 AM
